Effect of Zoledronic Acid Dosing in Women With Metastatic Breast Cancer

This randomized clinical trial examines whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients with metastatic breast cancer involving bone who had previously received a standard dosing regimen of zoledronic acid and/or pamidronate.

http://ift.tt/2jj9bcI